SNOA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sonoma Pharmaceuticals Inc (SNOA) is not a good buy for a beginner, long-term investor at this time. The stock shows bearish technical indicators, no significant positive catalysts, and weak financial performance, making it unsuitable for long-term investment goals.
The MACD is negative and expanding downward, RSI is neutral but leaning towards oversold territory, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 2.536, with resistance levels at 3.002 and 3.146. Overall, the technical outlook is bearish.
The company's gross margin increased by 6.48% YoY, reflecting improved operational efficiency.
No recent news or significant trading trends. Financial performance shows declining net income (-11.75% YoY) and EPS (-23.81% YoY). Stock trend analysis predicts further declines in the next week (-4.59%) and month (-6.54%).
In Q3 2026, revenue increased by 22.03% YoY to $4,349,000, but net income dropped to -$819,000 (-11.75% YoY), and EPS fell to -0.48 (-23.81% YoY). Gross margin improved to 37.94% (+6.48% YoY), but overall profitability remains weak.
No analyst rating or price target data available.
